Nephrocare Health shares list at 7% premium over IPO price

Synopsis

Nephrocare Effectively being Services and products debuted on stock exchanges with a 7% top rate, opening at Rs 491.70 on BSE and Rs 490 on NSE. The firm’s Rs 871.39 crore IPO saw noteworthy query, with QIBs and NIIs main subscriptions. Nephrocare, India’s largest dialysis provider, aims to make utilize of IPO proceeds for debt bargain and growth.

Hear to this text in summarized structure

Shares of Nephrocare Effectively being Services and products listed at 7% top rate over the IPO designate on Thursday. The stock opened at Rs 491.70 and Rs 490 at BSE and NSE, respectively, in comparison with its project designate of Rs 460.

The Rs 871.39 crore IPO saw noteworthy query, with the project subscribed 14.08 instances overall. Certified institutional merchants led the bidding, subscribing their part nearly 27 instances, whereas non-institutional investors grunt cease to 25 instances. Retail participation used to be extra measured at 2.36 instances, in step with broader trends the build particular person investors possess changed into selective amid a crowded well-known market calendar.

Nephrocare raised Rs 260.26 crore from anchor investors before the project, offering early steadiness to the book. The IPO comprised a new project of Rs 353.75 crore and a proposal for sale of Rs 517.64 crore. Proceeds from the brand new project will doubtless be feeble primarily to slice debt and make stronger growth of dialysis centres, whereas the OFS allows sleek investors to in part monetise their holdings.

Founded in 2010, Nephrocare is India’s largest dialysis companies and products provider and among the many largest in Asia. As of September 2025, the firm operated 519 clinics all over India and settle in one other country markets, in conjunction with the Philippines, Uzbekistan and Nepal. Practically 78% of its centres would be found in tier II and tier III cities, positioning the firm to lift pleasure in rising query for affordable power care in underserved areas.

In FY25, Nephrocare served over 29,000 sufferers and carried out nearly 2.9 million dialysis remedies, accounting for roughly 10% of India’s complete dialysis affected person imperfect. The firm follows an asset-mild mannequin, working dialysis objects by plan of partnerships with main scientific institution chains similar to Max, Fortis, CARE, Wockhardt and Paras Healthcare.

Financially, Nephrocare has delivered sturdy bid, with earnings rising 34% and profit after tax leaping 91% in FY25. EBITDA margins stood at 22%, reflecting working leverage from scale. Then again, analysts possess flagged valuation concerns. At the project designate, the stock is valued at over 160 instances post-project earnings, vastly increased than most listed healthcare peers.

With a 7% grey market top rate, Nephrocare’s list is expected to be actual. Mighty will rely on broader market sentiment and institutional keeping behaviour once anchor lock-ins originate to stride out in January and March.

(Disclaimer: Solutions, solutions, views and opinions given by the experts are their occupy. These enact now not signify the views of Financial Times)

…extraless

…extraless